{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001472079,0.0002229572,0.000321848,0.000237565,0.0003192041,0.00005452413,0.0004345933,0.00006277249,0.00002819108],"category_scores_gemma":[0.0003162748,0.0001885213,0.00004065797,0.0002364386,0.00031575,0.0004960103,0.0001146667,0.0002206815,0.00001148593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007192917,"about_ca_system_score_gemma":0.000187147,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005394027,"about_ca_topic_score_gemma":0.0002557347,"domain_scores_codex":[0.9979633,0.00007268408,0.0004977415,0.0004987543,0.0006480988,0.0003194262],"domain_scores_gemma":[0.9989287,0.00008326452,0.000418802,0.0002941811,0.00007699652,0.0001981032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004080785,0.04510146,0.5133196,0.0005868485,0.0001045728,0.0003409757,0.1472217,0.1055449,0.1654172,0.006776556,0.006697364,0.004808026],"study_design_scores_gemma":[0.07106864,0.006063308,0.3551559,0.001383645,0.00003130038,0.000005031222,0.002546733,0.005308366,0.5455379,0.01099545,0.0003484873,0.001555189],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979638,0.000004454456,0.000007003036,0.0005890472,0.0003531634,0.0007553838,0.00002345476,0.00002217766,0.0002815362],"genre_scores_gemma":[0.9992567,0.00000122249,0.00005279837,0.0001712517,0.0001323732,0.0000393431,0.00001185949,0.0000267872,0.0003077131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3801208,"threshold_uncertainty_score":0.7687674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03587327682816752,"score_gpt":0.3115781625913163,"score_spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}